Table 2.
Randomized trials of zoledronic acid in early breast cancer.
| Study | Number Design | HR | Comment | |
|---|---|---|---|---|
| ABCSG-12 | 1803 | Premenopausal | HR 0.64; 95% CI 0.46–0.91; p = 0.01 | Significantly fewer recurrences in ET +/- ZA patients receiving ZA |
| Z-FAST | 602 | Postmenopausal | HR 0.80; 95% CI 0.45–1.41; NS | Trend towards fewer recurrences in ET + early vs. delayed ZA patients treated with ZA |
| ZO-FAST | 1065 | Postmenopausal | HR 0.59; 95% CI 0.38–0.92; p = 0.0176 | Significantly fewer recurrences in ET + early vs. delayed ZA patients receiving ZA |
| E-ZO-FAST | 527 | Postmenopausal | HR 1.76; 95% CI 0.83–3.69; NS | Trend towards more recurrences in ET + early vs. delayed ZA patients treated with ZA |
| AZURE | 3360 | Pre/postmenopausal | HR 0.98; 95% CI 0.85–1.13; NS | No effect of ZA in addition to standard CT and/or ET +/- ZA therapy |
CI, confidence interval; CT, chemotherapy; ET, endocrine therapy; HR, hazard ratio; NS, not significant; ZA, zoledronic acid. See text for explanation of study name acronyms.